Savara Stock Discussion

$Savara (SVRA.US)$
After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Savara. “BLA submission, coupled with the submission of the MAA to the EMA by the end of 2025, are major regulatory mileston...

$Savara (SVRA.US)$
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
Savara Inc. (Nasdaq: SVRA) announced that a new episode of The Balancing Act® on Lifetime TV's Behind the Mystery™ series is featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP). The episode, sponsored by Savara, focuses on an aPAP patient's diagnostic journey and includes insights from Dr. Bruce Trapn...

$Savara (SVRA.US)$ Phase 3 update will be presented Monday.. keep watch

$Savara (SVRA.US)$ Reuters· just
Savara Announces Expanded Access Program (Eap) for Molgramostim Inhalation Solution (Molgramostim) for Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap)

$Savara (SVRA.US)$
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) has announced the Savara Early Access Program, an Expanded Access Program (EAP) for molgramostim inhalation solution to treat patients with autoimmune pulmonary alveolar proteinosis (aPAP). This program allows physicians to request molgramostim for eligible aPAP patients in select re...

Morning Movers
Gapping up
$Boeing (BA.US)$ shares rose by 4.1% in premarket US trading on Monday after the company tentatively agreed to a 25% pay increase for its biggest union, possibly averting a damaging strike.
Crypto-related stocks such as digital coin exchange $Coinbase (COIN.US)$ and crypto miners $CleanSpark (CLSK.US)$ and $MARA Holdings (MARA.US)$ advanced prior to the opening bell, buoyed by Bitcoin's gain, which ex...

$Nuburu (BURU.US)$ $Laser Photonics (LASE.US)$ $Savara (SVRA.US)$ $Avalon GloboCare (ALBT.US)$ $Intelligent Bio Solutions (INBS.US)$ $Versus Systems (VS.US)$
📊⚡️📊

$Savara (SVRA.US)$
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Savara Inc. (Nasdaq: SVRA) presented new data from the Phase 3 IMPALA-2 trial of molgramostim for autoimmune Pulmonary Alveolar Proteinosis (aPAP)at the ERS Congress 2024. The trial met its primary endpoint, showing significant i...